Sarepta outlines $1.2B-$1.4B 2026 revenue target as ELEVIDYS educational push ramps up
Source: SeekingAlpha
2026-02-25 20:28:37 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
- Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow
- Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
- Sarepta Therapeutics Q4 2025 Earnings Preview
- Regenxbio dealt win by appeals court in patent spat with Sarepta
Read the full article on Seeking Alpha
For further details see:
Sarepta outlines $1.2B–$1.4B 2026 revenue target as ELEVIDYS educational push ramps up
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
